← Back to headlines
Argenx's Vyvgart Meets Key Endpoints in Autoimmune Myositis Trial
Argenx has made progress as its drug, Vyvgart, successfully met key trial endpoints for the treatment of autoimmune myositis.
17 Aug, 08:28 — 17 Aug, 08:28
Sources
Showing 1 of 1 sources
Related Stories
Otedola Increases First HoldCo Stake with N20.7 Billion Share Purchase
56m ago
Alphabet Launches Inaugural Australian Dollar Bond Sale for AI Investment
2h ago
Paramount Seeks $1.88 Billion Bond in Merger Lawsuit
2h ago
German government open to selling Commerzbank stake to UniCredit under conditions
2h ago